Liminatus Pharma, Inc. (NASDAQ: LIMN) Enters MOU with Capital Trust Group for $30 Million Equity Investment Through Earn-Out Structure and Future Strategic Partnership | Intellectia.AI
Liminatus Pharma, Inc. (NASDAQ: LIMN) Enters MOU with Capital Trust Group for $30 Million Equity Investment Through Earn-Out Structure and Future Strategic Partnership
Written by Emily J. Thompson, Senior Investment Analyst
Liminatus Pharma's MOU with CTG: Liminatus Pharma has signed a Memorandum of Understanding with Capital Trust Group for a USD 30 million equity financing to support its immunotherapy research and development.
Investment Details: The investment is contingent on due diligence and the negotiation of definitive agreements, with plans to finalize these agreements in November 2025.
Future Cooperation: Alongside the equity investment, discussions for further strategic cooperation, including potential digital bond financing programs, are set to begin in mid-November.
Company Background: Liminatus Pharma focuses on developing next-generation immuno-oncology therapies, while CTG is a New Zealand-based investment management firm involved in large-scale financing across various sectors.
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
